Introduction:
OUD
DISORDER, DISORDERS
Pregnant individuals with substance use disorders face complex issues that may serve as barriers to treatment entry and retention. Several professional organizations have established recommendations on comprehensive, collaborative approaches to treatment to meet the needs of this population, but information on real-world application is lacking. Sites participating in the NIDA CTN0080 “Medication treatment for Opioid use disorder in expectant Mothers (MOMs)”—a randomized clinical trial of extended release compared to sublingual buprenorphine among pregnant and postpartum individuals (PPI)—were selected, in part, because they have a collaborative approach to treating PPI with opioid use disorder (OUD). However, organizational differences among sites and how they implement expert recommendations for collaborative care could impact study outcomes.